AbbVie (NYSE:ABBV), a $413 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Monday that its Phase 2 trial evaluating onabotulinumtoxinA (BOTOX) for upper limb essential tremor met its primary endpoint, showing statistically significant improvement compared to placebo.
The ELATE trial demonstrated that patients receiving onabotulinumtoxinA achieved greater reduction in the Tremor Disability Scale-Revised total unilateral score compared to placebo (-2.61 versus -1.61, p=0.029) at week 18. The study also met all six secondary endpoints.
Essential tremor affects approximately 25-60 million people worldwide and is the most common movement disorder. No new pharmacological treatments have been approved in the U.S. for this condition in more than 30 years.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.